386 related articles for article (PubMed ID: 18802929)
1. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation.
Leucci E; Cocco M; Onnis A; De Falco G; van Cleef P; Bellan C; van Rijk A; Nyagol J; Byakika B; Lazzi S; Tosi P; van Krieken H; Leoncini L
J Pathol; 2008 Dec; 216(4):440-50. PubMed ID: 18802929
[TBL] [Abstract][Full Text] [Related]
2. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
3. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma.
Kluiver J; Haralambieva E; de Jong D; Blokzijl T; Jacobs S; Kroesen BJ; Poppema S; van den Berg A
Genes Chromosomes Cancer; 2006 Feb; 45(2):147-53. PubMed ID: 16235244
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
[TBL] [Abstract][Full Text] [Related]
5. Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation.
De Falco G; Ambrosio MR; Fuligni F; Onnis A; Bellan C; Rocca BJ; Navari M; Etebari M; Mundo L; Gazaneo S; Facchetti F; Pileri SA; Leoncini L; Piccaluga PP
BMC Cancer; 2015 Oct; 15():668. PubMed ID: 26453442
[TBL] [Abstract][Full Text] [Related]
6. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression.
Leucci E; Onnis A; Cocco M; De Falco G; Imperatore F; Giuseppina A; Costanzo V; Cerino G; Mannucci S; Cantisani R; Nyagol J; Mwanda W; Iriso R; Owang M; Schurfeld K; Bellan C; Lazzi S; Leoncini L
Int J Cancer; 2010 Mar; 126(6):1316-26. PubMed ID: 19530237
[TBL] [Abstract][Full Text] [Related]
7. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.
Onnis A; De Falco G; Antonicelli G; Onorati M; Bellan C; Sherman O; Sayed S; Leoncini L
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20930934
[TBL] [Abstract][Full Text] [Related]
8. Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions.
Haralambieva E; Schuuring E; Rosati S; van Noesel C; Jansen P; Appel I; Guikema J; Wabinga H; Bleggi-Torres LF; Lam K; van den Berg E; Mellink C; van Zelderen-Bhola S; Kluin P
Genes Chromosomes Cancer; 2004 May; 40(1):10-8. PubMed ID: 15034863
[TBL] [Abstract][Full Text] [Related]
9. Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development.
Tagawa H; Karube K; Tsuzuki S; Ohshima K; Seto M
Cancer Sci; 2007 Sep; 98(9):1482-90. PubMed ID: 17608773
[TBL] [Abstract][Full Text] [Related]
10. Combined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis.
Busch K; Borkhardt A; Wössmann W; Reiter A; Harbott J
Haematologica; 2004 Jul; 89(7):818-25. PubMed ID: 15257933
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.
Toyota M; Suzuki H; Sasaki Y; Maruyama R; Imai K; Shinomura Y; Tokino T
Cancer Res; 2008 Jun; 68(11):4123-32. PubMed ID: 18519671
[TBL] [Abstract][Full Text] [Related]
12. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53.
Ramqvist T; Magnusson KP; Wang Y; Szekely L; Klein G; Wiman KG
Oncogene; 1993 Jun; 8(6):1495-500. PubMed ID: 8502475
[TBL] [Abstract][Full Text] [Related]
13. Frequent aberrations of chromosome 8 in aggressive B-cell non-Hodgkin lymphoma.
Pienkowska-Grela B; Witkowska A; Grygalewicz B; Rymkiewicz G; Rygier J; Woroniecka R; Walewski J
Cancer Genet Cytogenet; 2005 Jan; 156(2):114-21. PubMed ID: 15642390
[TBL] [Abstract][Full Text] [Related]
14. Topological organization of the MYC/IGK locus in Burkitt's lymphoma cells assessed by nuclear halo preparations.
Rätsch A; Joos S; Kioschis P; Lichter P
Exp Cell Res; 2002 Feb; 273(1):12-20. PubMed ID: 11795942
[TBL] [Abstract][Full Text] [Related]
15. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
16. Constitutive activation of oncogenes by chromosomal translocations in B-cell derived tumors.
Klein G
AIDS Res; 1986 Dec; 2 Suppl 1():S167-76. PubMed ID: 3030345
[TBL] [Abstract][Full Text] [Related]
17. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
18. Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma.
Kluiver J; van den Berg A; de Jong D; Blokzijl T; Harms G; Bouwman E; Jacobs S; Poppema S; Kroesen BJ
Oncogene; 2007 May; 26(26):3769-76. PubMed ID: 17173072
[TBL] [Abstract][Full Text] [Related]
19. Positioning of cervical carcinoma and Burkitt lymphoma translocation breakpoints with respect to the human papillomavirus integration cluster in FRA8C at 8q24.13.
Ferber MJ; Eilers P; Schuuring E; Fenton JA; Fleuren GJ; Kenter G; Szuhai K; Smith DI; Raap AK; Brink AA
Cancer Genet Cytogenet; 2004 Oct; 154(1):1-9. PubMed ID: 15381365
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma.
Arcinas M; Heckman CA; Mehew JW; Boxer LM
Cancer Res; 2001 Jul; 61(13):5202-6. PubMed ID: 11431360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
